Linda Stein Gold, MD

Panelists discuss how icotrokinra represents a novel oral peptide that selectively blocks the IL-23 receptor, offering the trusted safety profile of IL-23 inhibition in an oral formulation with high selectivity and no off-target effects.

Panelists discuss how second-generation PDE4 inhibitors, such as orismilast, aim to improve upon apremilast’s efficacy while maintaining safety, with phase 2 data showing PASI 75 rates up to 50%.

Panelists discuss how emerging TYK2 inhibitors such as brepocitinib and ESK001 target the JAK/STAT pathway to block IL-23 and IL-17 signaling, showing promising phase 2 results with PASI 100 rates around 33% and PASI 75 rates of 64%.

Panelists discuss how effective shared decision-making involves clinicians presenting 2 to 3 optimal treatment options based on patient-specific factors rather than overwhelming patients with all possibilities or making unilateral decisions, ultimately improving treatment adherence.

Panelists discuss how many eligible patients with psoriasis remain undertreated despite advanced therapy availability due to patient discontinuation from topical burden, injection anxiety, and the historical lack of effective oral options with good safety profiles.

Panelists discuss how modern topical treatments have evolved beyond traditional corticosteroids to include more effective nonsteroidal options, such as tapinarof and roflumilast, which provide better long-term control and can complement systemic therapies.

Panelists discuss how plaque psoriasis affects 0.4% to 8% of the global population, with high-impact areas such as the scalp (up to 80% of patients) and nails (25% of patients) significantly impacting quality of life and warranting systemic therapy consideration.

In this set of interviews, 6 leaders in the field of dermatology highlight their experiences at the 2025 EADV Congress.

This EADV 2025 interview featuring Linda Stein Gold, MD, highlights her team’s findings on icotrokinra versus placebo and versus deucravacitinib in psoriasis.

These interviews with Chovatiya and Stein Gold highlight a variety of key points from the dermatology-centric EADV Congress 2025 meeting in Paris, France.

In a new interview at the DERM2025 Conference, Stein Gold highlighted several topical options for patients with psoriasis outside of topical steroids.

FDA approval of topical delgocitinib marks a long-awaited treatment milestone for adults with chronic hand eczema.

Experts discuss key takeaways for dermatologists managing atopic dermatitis with JAK inhibitors, emphasizing the importance of individualized treatment plans, monitoring for safety and efficacy, and balancing the benefits of JAK inhibitors with potential risks, especially in long-term use.

Experts discuss how clinical judgment guides the decision to increase the dose of a JAK inhibitor, considering factors like patient response and symptom severity, and how often dose escalation is implemented in practice based on individual patient needs.

Experts discuss how data from studies like JADE EXTEND, Heads Up Extension, and LEVEL UP, showing improved outcomes with JAK inhibitors in patients who failed biologic therapy, influence their clinical practice and decision-making when considering switching systemic therapies for patients with atopic dermatitis.

Experts discuss situations where an oral JAK inhibitor might be prescribed initially over a biologic for moderate to severe atopic dermatitis (AD), noting advantages such as oral administration, quicker onset of action, and convenience, which may make it a preferred option for some patients.

Experts discuss the current place of JAK inhibitors in atopic dermatitis management, highlighting their role as an effective oral treatment option within the broader spectrum of therapies, including topical treatments and biologics, depending on disease severity and patient needs.

Experts discuss the necessary monitoring for patients prescribed JAK inhibitors, emphasizing regular assessments for safety and effectiveness, with adjustments in the monitoring plan based on factors such as smoking status and age.

Experts discuss how to effectively communicate the safety of JAK inhibitors to patients with atopic dermatitis, including how to address the FDA boxed warning by emphasizing the balance of risks and benefits and tailoring the conversation based on individual patient concerns and risk factors.

Experts discuss the FDA boxed warning for JAK inhibitors, which highlights risks such as venous thromboembolism (VTE), major adverse cardiac events (MACE), and malignancy originating from the ORAL surveillance trial. They compare these risks in the atopic dermatitis (AD) patient population with those seen in rheumatoid arthritis, noting generally lower incidences in patients with AD.

Experts discuss the long-term efficacy and safety of abrocitinib and upadacitinib in atopic dermatitis (AD), with sustained monotherapy results showing significant improvements in Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI), and Validated IGA-AD (vIGA-AD) scores. They also consider the safety profiles and potential risks, particularly in older patients, for long-term use of JAK inhibitors.

Experts discuss the significance of using selective JAK1 inhibitors for atopic dermatitis (AD), noting their targeted action compared with nonselective JAK inhibitors, and how JAK1 selectivity enhances both the efficacy and safety of these agents in treating AD.

Experts discuss the JAK/STAT signaling pathway’s critical role in immune response, highlighting the involvement of JAK enzymes in atopic dermatitis (AD) pathogenesis and how JAK inhibitors effectively reduce itch and inflammation, improving symptoms and skin clearance in AD.

Stein Gold highlights her team's findings on tapinarof cream (Vtama) 1% from the 48-week ADORING 3 extension for those aged 2 to 17 with atopic dermatitis.

This summary, featuring 4 leading experts, provides an overview of what dermatologists may look forward to during the AAD 2025 Annual Meeting.

Panelists discuss whether a treatment switch would be considered for a patient with 75% improvement in atopic dermatitis, weighing the benefits of continued treatment versus the potential for further improvement with a different therapy.

Panelists discuss how they define treatment non-responders in atopic dermatitis (AD), focusing on factors such as lack of significant improvement in symptoms, inadequate response to therapy, or failure to achieve treatment goals despite proper adherence and adjustments.

Panelists discuss the limited data on atopic dermatitis (AD) treatments in patients with skin of color, highlighting findings from other studies and real-world data to better understand treatment efficacy and safety in this diverse patient population.

Panelists discuss switching from dupilumab to other IL-13 inhibitors in atopic dermatitis (AD), reviewing real-world data (RWD) on the effectiveness, safety, and patient outcomes associated with these treatments.

Panelists discuss the safety of biologics in atopic dermatitis (AD), reviewing current understanding of their safety profiles, including long-term data, adverse events, and the overall risk-benefit analysis for patients using these agents.